Do very young Korean breast cancer patients have worse outcomes?

Annals of Surgical Oncology

Volumn 14, Issue 12, 2007, Pages 3385-3391

  Kim, Jeong Kyeung ^a   Kwak, Beom Seok ^a   Lee, Jung Sun ^a   Hong, Soo Jung ^a   Kim, Hee Jeong ^a   Son, Byung Ho ^a   Ahn, Sei Hyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Breast cancer; Prognosis; Young age

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER STAGING; COMPARATIVE STUDY; HISTOLOGY; HUMAN; KOREA; LYMPH NODE METASTASIS; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PREMENOPAUSE; PROGNOSIS; SURVIVAL RATE;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; KOREA; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 36348962946     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9345-9     Document Type: Article

References (41)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1999. National Cancer Institute: Bethesda, MD, 2002
2. Kothari AS, Beechey-Newman N, D'Arrigo C, et al. Breast carcinoma in women age 25 years or less. Cancer 2002;94:606-14
3. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M. D. Anderson Cancer Center experience. Cancer 2001;92:2523-8
4. Love RR, Due MB, Dinh NV, Quy TT, Xin Y, Havighurst TC. Young age as an adverse prognostic factor in premenopausal women with operable breast cancer. Clin Breast Cancer 2002;2:294-8
5. Dubsky PC, Gnant MF, Taucher S, et al. Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer 2002;3:65-72
6. Biffl WL, Myers A, Franciose RJ, Gonzalez RJ, Darnell D. Is breast cancer in young Latinas a different disease? Am J Surg 2001;182:596-600
7. Yildirim E, Dalgic T, Berberoglu U. Prognostic significance of young age in breast cancer. J Surg Oncol 2000;74:267-72
8. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcomes? J Surg Res 2003;113:109-13
9. Han W, Kim SW, Park LA, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 2004;4:82
10. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74
11. Kang HS, Yang HK, Noh DY, et al. Breast cancer of 35 years old or less. J Korean Breast Cancer Soc 1998;30:262-71
12. Jmor S, Al-Sayer H, Heys SD, et al. Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Surg Edinb 2002;47:693-9
13. Kothari AS, Fentiman IS. Breast cancer in young women. Int J Clin Pract 2002;56:184-7
14. Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 to stage III breast cancer in young women. J Am Coll Surg 2000;190:523-9
15. Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2002. J Korean Breast Cancer Soc 2004;7:72-83
16. Miller BA, Kolonel LN, Bernstein L. Racial/Ethnic Patterns of Cancer in the United States, 1988-1992. National Cancer Institute: Bethesda, MD, 1996
17. Korea Central Cancer Registry, Ministry of Health and Welfare, Republic of Korea. 2002 Annual Report of the Korea Central Cancer Registry. Korea Central Cancer Registry: Seoul, Korea, 2003
18. Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer 1997;33:425-8
19. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program (1997-2001). National Cancer Institute: Bethesda, MD
20. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002;13:273-9
21. Ashley S, Royle GT, Corder A, et al. Clinical, radiological and cytological diagnosis of breast cancer in young women. Br J Surg 1989;76:835-7
22. Boyages J, Chua B, Taylor R, et al. Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg 2002;89:789-96
23. Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994;12:888-94
24. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000;320:474-8
25. Schmidt RT, Tsangaris TN, Cheek JH. Breast cancer in women under 35 years of age. Am J Surg 1991;162:197-201
26. Muscolino G, Villani C, Bedini AV, Luini A, Salvadori B. Young age is not an ominous prognostic factor in breast cancer patients. Tumori 1987;73:233-5
27. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-97
28. Vrieling C, Collette L, Fourquet A, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 2003;39:932-44
29. Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radial Oncol Biol Phys 2003;57:724-31
30. Neuschatz AC, DiPetrillo T, Safaii H, Price LL, Schmidt-Ullrich RK, Wazer DE. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy. Cancer 2003;97:30-9
31. Elkhuizen PH, van Slooten HJ, Clahsen PC, et al. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol 2000;18:1075-83
32. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-32
33. Zhou P, Recht A. Young age and outcome for women with early-stage invasive breast carcinoma. Cancer 2004;101:1264-74
34. Shannon C, Smith IE. Breast cancer in adolescents and young women. Eur J Cancer 2003;39:2632-42
35. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990;1:183-8
36. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34:632-40
37. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young. women with breast cancer: need for tailored treatments.J Natl Cancer Hist Monogr 2001;(30):44-51
38. Aebi S, Castiglione-Gertsch M. Adjuvant endocrine therapy for the very young patients. Breast 2003;12:509-15
39. FitzGerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCAl mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:143-9
40. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642-9
41. Choi DH, Lee MH, Bale AE, Carter D, Haffty BG. Incidence of BRCAl and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 2004;22:1638-45